Objective. To evaluate the effectiveness of a combined strategy of human papillomavirus virus (HPV) vaccination and high-risk HPV screening to reduce the occurrence of anogenital and oropharyngeal neoplasms among men who have sex with men, people with HIV, homeless people, transgender women, female sex workers and rape victims. Materials and methods. This mixed methods study evaluates the effectiveness of a combined vaccination-screening strategy to reduce HPV prevalence/incidence and occurrence of cervical intraepithelial neoplasms grade 2+ and/or anal intraepithelial neoplasms grade 2+, using Kaplan-Meier. The time-to-event method will evaluate time from positive results for specific anogenital HPV to incidence of anogenital lesions containing that HPV type. Results. People vaccinated against HPV and screened for HPV as a primary test will have lower prevalence and incidence of HPV infection and consequently lower frequency of HPV-related anogenital and oropharyngeal lesions. Conclusions. This study will generate scientific evidence on effectiveness of a combined vaccination-screening strategy to reduce the burden of HPV-associated neoplasms.

No abstract

Objective. To measure HPV vaccine acceptance in diverse Mexican adult populations, taking into account HIV status. Materials and methods. A total of 1 329 men and women, with and without HIV, participated in one of three intervention studies, offering HPV vaccination, carried out in the states of Morelos, Tlaxcala and Mexico City; either the bivalent (Morelos n=103, Tlaxcala n=127) or quadrivalent HPV-vaccine (Mexico City n=1 099) was offered. Results. HPV vaccine was accepted by 80.3% of participants; acceptance was higher in people living with HIV than those without (84.4 vs. 78%, p=0.004). Women had greater HPV infection knowledge (p<0.0001) than men and slightly higher (p=0.4) vaccine acceptance. The main reason for vaccine non-acceptance among HIV-positive participants was their doctor recommended they not get vaccinated. Conclusion.

No abstract

Objetivo. Estimar la prevalencia de sintomatología depresiva en adolescentes y adultos mexicanos. Material y métodos. La Encuesta Nacional de Salud y Nutrición 2022 evaluó la prevalencia de sintomatología depresiva mediante la Escala de Depresión del Centro de Estudios Epidemiológicos (CESD-7). En adolescentes se estimó el puntaje promedio y en adultos la prevalencia de sintomatología depresiva. Resultados. En adolescentes el puntaje promedio de la CESD-7 fue 3.2. El 16.7% de los adultos tiene sintomatología depresiva, siendo mayor en adultos mayores (38.3%) que en adultos (11.3%). Se observaron mayores prevalencias en mujeres, adultos con índice de bienestar bajo y en adultos mayores residentes del área rural. Conclusión. A nivel nacional la prevalencia de sintomatología depresiva es similar a lo estimado en 2018-19. Se deben orientar acciones para mejorar la salud mental de la población, particularmente el diagnóstico y tratamiento de personas con mayor sintomatología depresiva como son mujeres, adultos con bajo índice de bienestar y residentes de área rural.